Steven J. Meyer
Director of Finance/CFO at JVM Capital LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jay Madary | M | - |
Jvm Realty Corp.
| - |
| Clare Trachtman | F | - | 24 years | |
| Steve Boyack | M | - |
Jvm Realty Corp.
| 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John N. Kapoor | M | 80 | 27 years | |
| Michael L. Babich | M | 47 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 8 years |
| Andrew Long | M | 58 | 2 years | |
| Harry Kraemer | M | 69 | 11 years | |
| Robert Parkinson | M | 73 | - | |
| Douglas Boothe | M | 60 | - | |
| Saeed Motahari | M | 58 | 2 years | |
| Alan D. Weinstein | M | 81 | 11 years | |
| Franc E. Del Fosse | M | 52 | - | |
| Martin K. McCarthy | M | 65 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 5 years |
| Patrick P. Fourteau | M | 77 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 10 years |
| Gail Fosler | F | 76 | 14 years | |
| Albert P. L. Stroucken | M | 76 | 19 years | |
| James R. Gavin | M | 78 | 18 years | |
| Terry Rappuhn | F | 67 | 5 years | |
| Bruce Kutinsky | M | 58 | 9 years | |
| Paul Freiman | M | 89 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Joseph Martin | M | 85 | - | |
| Darryl S. Baker | M | 55 | - | |
| Kenneth S. Abramowitz | M | 73 | 10 years | |
| Joseph P. Bonaccorsi | M | 59 | - | |
| Kornelis Storm | M | 79 | 15 years | |
| Ronald M. Johnson | M | 78 | 16 years | |
| Brian Tambi | M | 78 |
Insys Pharma, Inc.
| 13 years |
| Sean Brynjelsen | M | 52 | 9 years | |
| Timothy A. Dick | M | 53 | 6 years | |
| Carole J. Shapazian | F | 80 | 16 years | |
| Richard Mallery | M | 86 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Gregory Paul Watson | M | 68 | 12 years | |
| Daniel Douglas von Hoff | M | 76 | - | |
| Brian Anderson | M | 73 | 13 years | |
| Thomas T. Stallkamp | M | 77 | 22 years | |
| Michael P. Stehn | M | - | 30 years | |
| Vaseem Mahboob | M | 55 | - | |
| Andrece Housley | M | 56 | - | |
| Pierre LaPalme | M | 83 | 9 years | |
| Fabrizio Bonanni | M | 78 | 25 years | |
| John A. McKenna | M | 56 | - | |
| John D. Forsyth | M | 76 | 19 years | |
| Wilson Troutman | M | 69 | 8 years | |
| Elizabeth Bohlen | F | - | - | |
| John Greisch | M | 68 | 7 years | |
| Jon W. McGarity | M | 82 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 1 years |
| James Saccaro | M | 51 | 21 years | |
| Geertrui Vanhove | M | 59 | 2 years | |
| Adrienne Graves | M | 69 | 8 years | |
| Jonathan Kafer | M | 60 | - | |
| Randall Pollard | M | 52 | - | |
| Walter E. Boomer | M | 85 | - | |
| Santosh Vetticaden | M | 65 | 2 years | |
| Rohit Vishnoi | M | 63 | - | |
| Bernard A. Fox | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Mary Ladone | F | 57 | 16 years | |
| Richard Marritt | M | - | 15 years | |
| Ferrington Leonard C. | M | - | 2 years | |
| Todd Young | M | 52 | - | |
| Robert Peterson | M | 67 | 13 years | |
| Carsten Brockmeyer | M | - | 7 years | |
| Kent Stemper | M | - | 13 years | |
| Ramesh Acharya | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Thomas Englese | M | 50 | 6 years | |
| Michael Griffith | M | - | 13 years | |
| Gerard Wallace | M | - | 5 years | |
| Eric Carlson | M | - | 1 years | |
| Christoph Elser | M | 64 | 5 years | |
| Lawrence T. Gibbons | M | 72 | 5 years | |
| Jean-Paul Ruiz-Funes | M | - | 4 years | |
| Joseph G. Darling | M | 66 | 6 years | |
| Alan L. Heller | M | 70 | 4 years | |
| Vernon R. Loucks | M | 89 | 33 years | |
| Lawrence D. Damron | M | 77 | 12 years | |
| Jan Reed | F | 64 | 6 years | |
| Randel Woodgrift | M | 62 | 14 years | |
| John F. Gaither | M | 74 | 18 years | |
| Donald W. Joseph | M | - | 34 years | |
| Thomas Keuer | M | 65 | 6 years | |
| Bruce H. McGillivray | M | 68 | 8 years | |
| Mark E. Spring | M | - | 1 years | |
| William E. Saxelby | M | 67 | 21 years | |
| Anastassios D. Retzios | M | 72 | 5 years | |
| Robert J. Deans | M | 71 | 6 years | |
| Sebastian J. Bufalino | M | 63 | 16 years | |
| Troy Ignelzi | M | 56 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 2 years |
| Melissa Guerdan | F | 50 | 4 years | |
| John W. Colloton | M | 93 | 14 years | |
| Michael Mussallem | M | 71 | 21 years | |
| Frank C. Becker | M | 88 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Norbert Riedel | M | 66 | 15 years | |
| Martin Emerson | M | 60 | 12 years | |
| Andrew Cleeland | M | - | 2 years | |
| Michel Demaré | M | 67 | 3 years | |
| Brent Hatzis-Schoch | M | 59 | 4 years | |
| Michael Baughman | M | 59 | - | |
| Paul G. Marshall | M | 64 | 6 years | |
| Toni L. Wayne | F | 71 | 8 years | |
| Venkat Reddy Goskonda | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Matthew Thomas | M | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steven J. Meyer
- Personal Network
